|Trade names||Survanta, Alveofact|
|Drug class||Pulmonary surfactant|
|Main uses||Infant respiratory distress syndrome|
|Side effects||Low oxygen, slow heart rate, low blood pressure, high blood pressure, apnea, blockage of the endotracheal tube|
|In the trachea|
|Onset of action||Within minutes|
|Duration of action||2 to 3 days|
|Typical dose||25 mg/kg|
Beractant, sold under the brand name Survanta, is a medication used to prevent and treat respiratory distress syndrome in newborns. Specifically it is used in those who are born premature. It is given in the trachea. Effects begin within minutes and may last for up to 3 days.
Common side effects include slow heart rate, low oxygen, low blood pressure, high blood pressure, apnea, and blockage of the endotracheal tube. Other side effects may include sepsis. It is a pulmonary surfactant derived from cows.
It is generally give at a dose of 25 mg/kg four times.
It is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.
- "Beractant Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 10 January 2022.
- "Survanta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 January 2021. Retrieved 10 January 2022.
- Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. (April 2005). "A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants". Pediatrics. 115 (4): 1018–29. doi:10.1542/peds.2004-2183. PMID 15805380. S2CID 40458323.